OSI-7904
Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H24N4O6 |
Molar mass | 500.511 g·mol−1 |
3D model (JSmol) | |
SMILES
|
OSI-7904 is a noncompetitive liposomal thymidylate synthase inhibitor. OSI-7904 is a benzoquinazoline folate analog with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication.[1]
OSI-7904L is a liposome-encapsulated formulation of OSI-7904. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904.[1]
Its effect on solid tumors is currently under evaluation.[2][3][4]
References
- 1 2 "NCI Drug Dictionary: OSI-7904L". National Cancer Institute.
- ↑ Ricart AD, Berlin JD, Papadopoulos KP, et al. (December 2008). "Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors" (PDF). Clin. Cancer Res. 14 (23): 7947–55. doi:10.1158/1078-0432.CCR-08-0864. PMID 19047127. S2CID 14215154.
- ↑ "Phase I study of liposomal thymidylate synthase inhibitor (TSI) OSI-7904L in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 2003 (abstr 561)".
- ↑ Clamp AR (2008). "A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology April 2008, Volume 61, Issue 4, pp 579-585". Cancer Chemotherapy and Pharmacology. 61 (4): 579–585. doi:10.1007/s00280-007-0509-5. PMID 17520255. S2CID 26018991.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.